Bryan Callen

whereby a drug developer would match the state's investment on the front end by assuming all legal, logistical, and financial risks associated with securing the FDA's approval to pursue clinical research trials for the development of Ibogaine as a breakthrough therapeutic treatment for opioid use disorder, co-occurring substance use disorder, and any other mental health conditions for which it demonstrated efficacy.

We had a high-profile public announcement on May 31, 2023, to announce this exploration. We conducted three very high-profile public hearings, each of which lasted about five hours, about all aspects of Ibogaine. These hearings are available online as a formal part of the public record for anyone to view. The first hearing involved the science of Ibogaine.

We had a high-profile public announcement on May 31, 2023, to announce this exploration. We conducted three very high-profile public hearings, each of which lasted about five hours, about all aspects of Ibogaine. These hearings are available online as a formal part of the public record for anyone to view. The first hearing involved the science of Ibogaine.

We had a high-profile public announcement on May 31, 2023, to announce this exploration. We conducted three very high-profile public hearings, each of which lasted about five hours, about all aspects of Ibogaine. These hearings are available online as a formal part of the public record for anyone to view. The first hearing involved the science of Ibogaine.

It included the testimony of Dr. Nolan Williams, Dr. Kenneth Alper, and Dr. Deborah Mash, who has been a pioneer around the development of Ibogaine's application to opioid addiction for over 30 years now. We had a second public hearing, which involved the testimonials of individuals who had received, provided, or had sent loved ones for Ibogaine treatment.

It included the testimony of Dr. Nolan Williams, Dr. Kenneth Alper, and Dr. Deborah Mash, who has been a pioneer around the development of Ibogaine's application to opioid addiction for over 30 years now. We had a second public hearing, which involved the testimonials of individuals who had received, provided, or had sent loved ones for Ibogaine treatment.

It included the testimony of Dr. Nolan Williams, Dr. Kenneth Alper, and Dr. Deborah Mash, who has been a pioneer around the development of Ibogaine's application to opioid addiction for over 30 years now. We had a second public hearing, which involved the testimonials of individuals who had received, provided, or had sent loved ones for Ibogaine treatment.

All of this was done in a very high profile and publicly because we wanted the people of Kentucky to understand all Aspects of this opportunity its profundity and the way it could which it could transform not just the lives of their families But the future of this state that second public hearing was one of the most moving public proceedings of which I have ever been a part and I don't know how anyone in

All of this was done in a very high profile and publicly because we wanted the people of Kentucky to understand all Aspects of this opportunity its profundity and the way it could which it could transform not just the lives of their families But the future of this state that second public hearing was one of the most moving public proceedings of which I have ever been a part and I don't know how anyone in

All of this was done in a very high profile and publicly because we wanted the people of Kentucky to understand all Aspects of this opportunity its profundity and the way it could which it could transform not just the lives of their families But the future of this state that second public hearing was one of the most moving public proceedings of which I have ever been a part and I don't know how anyone in

could listen to those testimonials which included one from Governor Perry and come away with any other conclusion but that Ibogaine must be developed as expeditiously and safely as possible for the sake of our brothers and sisters in this country. The third hearing which occurred at the request of the University of Kentucky which along with Andy Beshear fought this proposal every step of the way

could listen to those testimonials which included one from Governor Perry and come away with any other conclusion but that Ibogaine must be developed as expeditiously and safely as possible for the sake of our brothers and sisters in this country. The third hearing which occurred at the request of the University of Kentucky which along with Andy Beshear fought this proposal every step of the way

could listen to those testimonials which included one from Governor Perry and come away with any other conclusion but that Ibogaine must be developed as expeditiously and safely as possible for the sake of our brothers and sisters in this country. The third hearing which occurred at the request of the University of Kentucky which along with Andy Beshear fought this proposal every step of the way

centered on the question of whether the fda would even consider approving clinical trials given what was repeatedly asserted as the unacceptable level of cardiac risk associated with its application

centered on the question of whether the fda would even consider approving clinical trials given what was repeatedly asserted as the unacceptable level of cardiac risk associated with its application

centered on the question of whether the fda would even consider approving clinical trials given what was repeatedly asserted as the unacceptable level of cardiac risk associated with its application

Within that hearing, we were able to procure the testimony of the scientist general who was in charge of controlled substances research at the FDA, a gentleman by the name of Dr. Javier Munez, along with his colleague, Dr. Walter Dunn, who sat on the FDA's advisory board of psychopharmacology. I believe he still sits on there.

Within that hearing, we were able to procure the testimony of the scientist general who was in charge of controlled substances research at the FDA, a gentleman by the name of Dr. Javier Munez, along with his colleague, Dr. Walter Dunn, who sat on the FDA's advisory board of psychopharmacology. I believe he still sits on there.

Within that hearing, we were able to procure the testimony of the scientist general who was in charge of controlled substances research at the FDA, a gentleman by the name of Dr. Javier Munez, along with his colleague, Dr. Walter Dunn, who sat on the FDA's advisory board of psychopharmacology. I believe he still sits on there.

And those gentlemen, after having heard the testimony as well as questioning from the University of Kentucky's representative, which suggested that the FDA would never approve it, began their testimony by saying, It has been asserted that the cardiac risk associated with Ibogaine would disqualify it from consideration by the FDA for clinical trials. That is absolutely and completely incorrect.